A bridge over troubled water—Extending induction for high‐risk neuroblastoma patients with poor end‐of‐induction response

Abstract

See referenced original article on pages 2967-2977, this issue.A subset of patients with high-risk neuroblastoma who have a poor end-of-induction response may benefit from receiving chemoimmunotherapy as bridge therapy before consolidation. Prospective studies evaluating this therapeutic approach and improved identification of biomarkers of response are warranted.